These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32667164)

  • 1. Dapagliflozin (Farxiga) for Preventing Hospitalization for Heart Failure.
    Tingen J; Gazewood JD
    Am Fam Physician; 2020 Jul; 102(2):115-116. PubMed ID: 32667164
    [No Abstract]   [Full Text] [Related]  

  • 2. Dapagliflozin (Farxiga) - a new indication for heart failure.
    Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023
    [No Abstract]   [Full Text] [Related]  

  • 3. Empagliflozin (Jardiance) for heart failure.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):177-178. PubMed ID: 33438858
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.
    Kondo H; Takahashi N
    Cardiovasc Res; 2019 May; 115(6):e54-e57. PubMed ID: 31077584
    [No Abstract]   [Full Text] [Related]  

  • 5. Dapagliflozin Cut Risk of Worsening Heart Failure.
    Slomski A
    JAMA; 2020 Jan; 323(4):301. PubMed ID: 31990313
    [No Abstract]   [Full Text] [Related]  

  • 6. NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.
    Adler AI; Douch E; Dunning L; Elliott N
    Lancet Diabetes Endocrinol; 2021 May; 9(5):261-263. PubMed ID: 33713596
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin in patients with heart failure and reduced ejection fraction.
    Colombo G; Casella R; Cazzaniga A; Casiraghi C;
    Intern Emerg Med; 2020 Apr; 15(3):515-517. PubMed ID: 32124206
    [No Abstract]   [Full Text] [Related]  

  • 10. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
    Katsiki N; Triposkiadis F
    Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
    [No Abstract]   [Full Text] [Related]  

  • 11. Is Dapagliflozin Cost-effective for Treating Heart Failure?
    Slomski A
    JAMA; 2021 Aug; 326(5):378. PubMed ID: 34342627
    [No Abstract]   [Full Text] [Related]  

  • 12. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
    Bhatt DL; Verma S; Braunwald E
    Cell Metab; 2019 Nov; 30(5):847-849. PubMed ID: 31693879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidiabetic Drug Approved to Reduce Risk of Kidney Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Sep; 121(9):25. PubMed ID: 34438427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In brief: Dapagliflozin (Farxiga) for chronic kidney disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):115. PubMed ID: 34544107
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction.
    Verma S
    Cardiovasc Res; 2020 Jan; 116(1):e8-e10. PubMed ID: 31850505
    [No Abstract]   [Full Text] [Related]  

  • 17. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
    Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
    Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
    [No Abstract]   [Full Text] [Related]  

  • 18. An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
    Yoshihara F; Imazu M; Hamasaki T; Anzai T; Yasuda S; Ito S; Yamamoto H; Hashimura K; Yasumura Y; Mori K; Watanabe M; Asakura M; Kitakaze M;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):183-190. PubMed ID: 29589153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin Safe and Effective for Heart Failure With Frailty.
    Slomski A
    JAMA; 2022 May; 327(20):1950. PubMed ID: 35608583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.